The right drug targets for the right patient – Using biomarkers to solve challenges in drug development
Protein biomarkers provide a dynamic and powerful approach to identify and understand novel drug targets in early in drug development. The pharmaceutical industry utilizes biomarkers to help uncover disease progression markers, responder signatures, diagnostic biomarkers, and potential new indications.
Leading experts will:
Share their opinions on how biomarkers can help drive early clinical phase trials
Discuss their work with biomarkers at present
Explore the history of protein biomarkers within their organization
Predict how the field will evolve to meet future challenges
Key learning objectives
From this webinar, you will gain an understanding of the challenges and solutions behind the use of protein biomarkers in drug discovery, and appreciate the use of protein biomarker solutions for patient stratification by disease severity.
Dr. Jürgen Braunger, Head of Cellular and Protein Biomarkers, Boehringer Ingelheim
Timothy Radstake MD, PhD, Executive Director Immunology Discovery & Distinguished Research Fellow Head Transformational and Translational Immunology Discovery (TTID), AbbVie
Dr. Christopher D. Whelan, Associate Director of Computational Biology, Biogen
Moderator: Dr. Matthew McArdle, Editor, SelectScience